26 May Lakewood-Amedex Inc. Appoints Chief Medical Officer And Chief Scientific Officer To Enhance Drug Development And Clinical Trials Programs
SARASOTA, Fla., May 26, 2016 /PRNewswire/ — Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has appointed Steve Miley, M.D., to serve as its Chief Medical Officer. Dr. Miley, currently a practicing physician and a member of the Company’s Board of Directors since 2008, brings to the Company significant medical experience relevant to the pharmaceutical industry, through many years of hospital emergency department practice, significant experience in clinical trials and as the CEO of a number of healthcare companies, both public and private.
Simultaneously the company announced today that it has appointed Steven A. Kates, Ph.D., to serve as its Chief Scientific Officer and Vice President, Regulatory Affairs. Dr. Kates has had a long career in drug development, pre-clinical development, regulatory affairs and clinical trial management.
Steve Parkinson, President and CEO remarked, “These experienced executives bring to Lakewood-Amedex important capabilities essential to us as our first human clinical trial is now underway and in the strategic planning of our next two INDs which we hope to file with the FDA as soon as possible.”
Dr. Miley is a graduate of University of South Florida College of Medicine. He is board certified in Emergency Medicine. He also holds certifications from the Advance Cardiac Life Support and the American Board of Quality Assurance & Utilization Review. In the early 80s he was founder and CEO of Family Medical Centers/National HMO the first Public company to develop and manage a large number of Urgent Care Centers. He also served as the President of the National Association for Ambulatory Care a national organization representing over 4,000 Urgent Care centers. He was the founder and Managing Director of Axcess Medical Imaging, as well as the founder of Physician Computer Systems, Inc., and founder, Chief Executive Officer of MedHost Inc. (currently in over 500 hospitals nationwide), both software development companies for the healthcare industry. In his over 33 years as a physician Dr. Miley held numerous hospital affiliations and directorships at facilities such as St. Joseph’s Hospital, Lykes Memorial Hospital, Manatee Memorial Hospital, Holmes Regional Medical Center, Palm Bay Family Medical Services and Bon Secours Venice Hospital. Currently he is a partner in a large hospital based multi-specialty group in Florida covering four hospitals.
Dr. Kates is a highly experienced pharmaceutical executive with over twenty-five years in R&D for both life science products and human therapeutics. Dr. Kates is regarded as a world leading chemist and industry expert in peptide design and manufacture in the biopharmaceutical industry. He has advanced several compounds through drug development from early pre-clinical to mid-stage clinical development and has been responsible for the successful development of clinical candidates for both 505(b)2 and NCE applications. He has held senior positions at Ischemix, Citius Pharmaceuticals, Surface Logix, Consensus and Millipore Corporation and has written or co-authored more than 100 articles, reviews, and patents and is an ad hoc reviewer for the NIH bio-organic and natural products study section. He has served as editor of ADMET for Medicinal Chemists: A Practical Guide and Solid-Phase Synthesis: A Practical Guide; guest editor of Biopolymers; and as a member of the Editorial Board of International Journal of Peptide Research and Therapeutics. An Adjunct Professor of Chemistry at Northeastern University and Visiting Professor of Chemistry at Brandeis University, Dr. Kates earned his B.S. in chemistry from Bates College, Ph.D. in Synthetic Organic Chemistry from Brandeis University and conducted post-doctoral studies at The Massachusetts Institute of Technology.
About Lakewood-Amedex, Inc.
Lakewood-Amedex is a privately held biopharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class anti-bacterial compounds, gene-silencing anti-virals, locally delivered and orally available nanoRNA therapeutics for acute and chronic diseases such as arthritis, inflammation, cancer. The Company’s products and technology are covered by an extensive patent portfolio consisting of 74 granted and/or issued patents and 13 pending patent applications filed on a worldwide basis covering all major pharmaceutical markets. The Company’s lead therapeutic candidate is a novel synthetic broad spectrum anti-bacterial proven to be effective in killing a wide range of gram-positive, gram-negative, and antibiotic-resistant bacteria and is currently in Phase 1/2a clinical trials.
This press release contains forward-looking statements that can be identified by terminology such as “expects”, “potential”, “suggests”, “may”, “will” or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are “forward-looking statements” that involve risk and uncertainties, which could cause the Company’s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company’s planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.
Steve Miley, M.D.
President and CEO
CMO and Director
(941) 255 2515
(941) 685 6533